Elutia to Participate at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum

11/13/24 4:05:00 PM ET

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

Get the next $ELUT alert in real time by email

SILVER SPRING, Md., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Elutia Inc. (NASDAQ:ELUT) ("Elutia" or the "Company"), a leader in drug-eluting biomatrix products, today announced that Dr. Randy Mills, President and Chief Executive Officer, Matt Ferguson, Chief Financial Officer, and Dr. Michelle LeRoux Williams, Chief Scientific Officer, will participate in 1x1 investor meetings at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum in New York on Thursday, November 21, 2024.

Institutional investors interested in meeting with management during the conference may reach out to their Canaccord representative.

About Elutia

Elutia develops and commercializes drug-eluting biomatrix products to improve compatibility between medical devices and the patients who need them. With a growing population in need of implantable technologies, Elutia's mission is humanizing medicine so patients can thrive without compromise. For more information, visit www.Elutia.com.

Investors:

Matt Steinberg

FINN Partners

[email protected]

Get the next $ELUT alert in real time by email

Elutia to Participate at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum

Chat with this insight

Recent Analyst Ratings for
$ELUT

$ELUT
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

CHIEF SCIENTIFIC OFFICER Williams Michelle Leroux converted options into 12,500 shares and covered exercise/tax liability with 3,951 shares, increasing direct ownership by 17% to 59,849 units (SEC Form 4)

PRESIDENT AND CEO Mills C Randal converted options into 27,084 shares and covered exercise/tax liability with 9,664 shares, increasing direct ownership by 7% to 253,941 units (SEC Form 4)

CHIEF FINANCIAL OFFICER Ferguson Matthew covered exercise/tax liability with 10,527 shares and converted options into 29,500 shares, increasing direct ownership by 7% to 310,705 units (SEC Form 4)

$ELUT
Market Insights

Live Market Insights

Lake Street Maintains Buy on Elutia, Raises Price Target to $10

Cantor Fitzgerald Maintains Overweight on Elutia, Raises Price Target to $11

Cantor Fitzgerald Maintains Overweight on Elutia, Raises Price Target to $11

$ELUT
Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Birchview Capital, Lp bought $206,958 worth of shares (140,000 units at $1.48) (SEC Form 4) (Amendment)

$ELUT
Financials

Live finance-specific insights

Elutia Announces Strong Third Quarter Results, Accelerating Toward Full Launch of EluPro® Antibiotic-Eluting BioEnvelope in 2025

Elutia to Report Third Quarter 2024 Financial Results on Thursday, November 14, 2024

SWK Holdings Provides Portfolio Update

$ELUT
SEC Filings

SEC Form 10-Q filed by Elutia Inc.

Amendment: SEC Form SCHEDULE 13G/A filed by Elutia Inc.

Elutia Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

$ELUT
Large Ownership Changes

This live feed shows all institutional transactions in real time.

SEC Form SC 13G filed by Elutia Inc.

SEC Form SC 13G/A filed by Elutia Inc. (Amendment)

$ELUT
Leadership Updates

Live Leadership Updates

Elutia Appoints Ryan Marques, Ph.D., MBA as Vice President of Operations

$ELUT
Press Releases

Fastest customizable press release news feed in the world

Elutia Announces Strong Third Quarter Results, Accelerating Toward Full Launch of EluPro® Antibiotic-Eluting BioEnvelope in 2025